Cancer Watch - Keeping up to date with the latest cancer news and developments throughout the world. Beating cancer one tweet at a time.........................
Joined October 2019
- Tweets 964
- Following 148
- Followers 74
- Likes 2,674
2 Photos and videos
Cancer Watch retweeted
Jun 12
#FDA approves a treatment for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer. fda.gov/drugs/resources-info…
ALT The image contains text on a blue and white background stating, "FDA approves a treatment for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer." The FDA logo is in the bottom left corner.
9
8
18
2,613
Cancer Watch retweeted
Jun 12
#FDA approves an adjuvant treatment for renal cell carcinoma. fda.gov/drugs/resources-info…
2
6
12
1,962
Cancer Watch retweeted
Jun 9
Sequential radiotherapy and immunotherapy (#iRT) provided longer overall survival than concurrent iRT for newly diagnosed advanced non–small cell lung cancer, with additional benefit from chemotherapy.
ja.ma/4oh4KRG
ALT Kaplan-Meier curves show real-world overall survival for refractory NSCLC treated with immunotherapy plus radiotherapy, comparing \"with\" vs. \"without chemotherapy\" (overlap-weighted & unweighted). Crude HR 1.11, Adjusted HR 0.85. A table of number at risk is below.
12
28
2,562
Cancer Watch retweeted
Jun 8
The concept of oligometastatic disease has reshaped the management paradigm for many solid tumours because some patients may achieve long-term disease control or even cure with aggressive local therapy. bmjoncology.bmj.com/content/…
8
12
1,497
Cancer Watch retweeted
Most assume Phase 1 oncology trials end early because of toxicity
In reality, strategic sponsor decisions is the leading cause
A difficult reality for patients who volunteer, accept risk, and place hope in research
@VivekSubbiah @pash22 @DavidHongMD
academic.oup.com/jnci/articl…
3
8
26
11,377
Cancer Watch retweeted
Landmark moment for European healthcare
First Joint Clinical Assessment under the EU HTA Regulation is now a reality.
A major milestone for EU healthcare and patient access to innovative medicines
@pash22 @SullivanProf @darioT_ @emahase_ @andrewgregory
health.ec.europa.eu/publicat…
3
3
8
1,089
Cancer Watch retweeted
Jun 5
EV Pembro continues to show why it’s a frontline standard for mUC. See our summary of @tompowles1’s 3.5-yr EV302 update at #ASCO26. Also don’t miss the wonderful discussant talk by @apolo_andrea #AdvInOnc26 @OncBrothers @OncUpdates @Ron_cology @KellyNFitz
oncupdates.com/article/ev-30…
2
8
987
Cancer Watch retweeted
Jun 5
Bayesian networks are increasingly recognised as powerful artificial intelligence tools for prognostication in oncology.
Learn more with this new study!
bmjoncology.bmj.com/content/…
1
1
115
Cancer Watch retweeted
Jun 4
Thank you @ASCO and the Patient Advocates who attended the “FDA United in Accelerating Progress for Patients” session. FDA celebrates National Cancer Survivors Month.
4
1
11
994
Cancer Watch retweeted
As #ASCO2026 highlights exciting advances in cancer care, we must not forget the oncology workforce crisis
Rising cancer incidence, workforce shortages and burnout threaten delivery of innovation especially in lower income countries #Oncology #CancerCare
theguardian.com/society/2026…
3
5
484
Cancer Watch retweeted
May 31
This is not simply a new pancreatic cancer drug.
It is a reminder that even “undruggable” biology can become treatable with persistence.
Daraxonrasib doubled median OS vs chemotherapy in RAS G12 metastatic pancreatic cancer: 13.2 vs 6.6 months.
A remarkable ASCO moment.
#ASCO26
@DrChoueiri @TiansterZhang @CathyEngMD @montypal @tompowles1 @brian_rini @cdanicas @GlopesMd @PGrivasMDPhD @nataliagandur @yekeduz_emre @neerajaiims @ASCO @ONCOassist @OpenMedicineHQ @MedwatchKate @scserendipity1 @CParkMD @urotoday @OncLive @crisbergerot @urologysummit @SuyogCancer @Larvol @IMG_Oncologists
24
277
1,354
192,349
Cancer Watch retweeted
May 31
#ChenZhiwei presents analysis from the phase 3 HARMONi-6 trial, where ivonescima chemotherapy improved OS vs tislelizumab chemotherapy in advanced sq-NSCLC (27.9 vs 23.7 months; HR 0.66).
#ASCO26 #LungCancer @ASCO @OncoAlert
1
13
15
1,475
Cancer Watch retweeted
May 31
RASolute 302 : Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
buff.ly/kw22hZ2
In this phase 3 trial of 500 patients with previously treated metastatic pancreatic ductal adenocarcinoma, the oral RAS(ON) inhibitor daraxonrasib significantly improved outcomes versus investigator’s-choice chemotherapy🧪 . Median overall survival doubled (13.2 vs. 6.6–6.7 months), while progression-free survival also improved 📈 substantially (7.2–7.3 vs. 3.5–3.6 months). Benefits were consistent across populations, including RAS G12-mutant disease. Daraxonrasib demonstrated a manageable safety profile, with fewer treatment discontinuations than chemotherapy. #PancreaticCancer
@EileenMOReilly
@WainbergZev
@DrHendifar
@MiteshBorad
@FilippoPietran4
@DrShubhamPant
@ChiaraCrem1
@DrGManji
@md_oberstein
@GarridoLagunaMD
@pashtoonkasi @CathyEngMD @marklewismd @manjuggm @ARosen380 @KoheiShitara @GillSharlene @BenWestphalen @graokane
3
42
112
5,039
Cancer Watch retweeted
May 31
Impressive daraxonrasib data.
From RT standpt, if RAS inhibition meaningfully prolongs dz control, local progression = more relevant
Future trials should test consolidative ablative RT in pts responding to darax (potentially leveraging RAS-mediated radiosens) #ASCO26 @OncoAlert
May 31
5. RASolute-302: Daraxonrasib (pan-RAS inhibitor) vs. chemo in 2L metastatic pancreatic adenocarcinoma:
- Majority of PDAC harbor RAS mutation (more than 90%)
- mOS (in all comers): 13.2mos vs. 6.7mos (HR: 0.40)
- Gr ≥ 3 AEs: 62% vs. 70%
- New SoC/paradigm shifting!!
6/6
x.com/rachnatshroff/status/2…
2
33
98
11,909
Cancer Watch retweeted
Immunotherapy timing debate continues…
New meta-analysis in JAMA Network Open suggests morning ICI administration may improve outcomes.
Interesting signal, but mostly retrospective data with confounding risk.
@cremieuxrecueil @oncology_bg @Eddie_Cliff
jamanetwork.com/journals/jam…
3
5
158
Cancer Watch retweeted
May 9
Two practice-informing trials at #ESMOBreast26 carry a broader lesson for oncology: sequencing #ADCs with the same payload class — here, a TOPO1 inhibitor — may not work simply by changing the target, linker, or PK.
BRE-354 from @ErikaHamilton9 @SarahCannonDocs and SATEEN from @PTarantinoMD @adawaksmd @DFCI_BreastOnc both speak to this important question.
This echoes what we have seen with PD-1 after PD-1 strategies: changing the partner drug does not necessarily overcome resistance to the same core mechanism. In RCC, two randomized phase III trials showed that this approach does not generally work:
TiNivo-2: shorturl.at/hP8AI
CONTACT-03: shorturl.at/litTw
with @montypal @motzermd @AlbigesL @BradMcG04 in @TheLancet
The biology of resistance matters. Mechanism matters. Payload matters.
@myESMO @ASCO @AACR @OncoAlert
3
37
76
7,177
Cancer Watch retweeted
New @FDAOncology approval
#zenocutuzumab for adults with advanced, unresectable or metastatic #cholangiocarcinoma harboring a neuregulin 1
@curecc @CharityAMMF @Cholangiocarci2 @AHPBA
1
1
40
Cancer Watch retweeted
May 5
In advanced nonsquamous #NonSmallCellLungCancer, tiragolumab plus atezolizumab and chemotherapy did not improve progression-free or overall survival compared with pembrolizumab plus chemotherapy, with similar safety profiles. ja.ma/4cPUJqt
ALT JAMA Oncology RCT: Tiragolumab plus atezolizumab & chemotherapy for advanced nonsquamous non-small cell lung cancer. Population: 353 male, 189 female, mean age 63.6. Intervention: 542 patients randomized. Findings: No statistically significant differences.
6
10
998
Cancer Watch retweeted
May 4
Maintenance rucaparib provided >5-year progression-free survival for 16% of patients with #PancreaticCancer and BRCA/PALB2 variants; resistance mechanisms were detected in half of those with disease progression. ja.ma/4w4ediJ
2
6
11
1,396